Latest filings (excl ownership)
8-K
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
12 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
10-Q
2024 Q1
Quarterly report
10 Apr 24
8-K
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
10 Apr 24
8-K
Other Events
9 Apr 24
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
8-K
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
11 Mar 24
S-8
Registration of securities for employees
15 Feb 24
10-K
2023 FY
Annual report
15 Feb 24
8-K
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
15 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
11 Dec 23
8-K
Regulation FD Disclosure
13 Nov 23
8-K
Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
1 Nov 23
10-Q
2023 Q3
Quarterly report
12 Oct 23
8-K
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
12 Oct 23
8-K
Entry into a Material Definitive Agreement
7 Sep 23
10-Q
2023 Q2
Quarterly report
13 Jul 23
8-K
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
13 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
4 May 23
10-Q
2023 Q1
Quarterly report
13 Apr 23
8-K
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
13 Apr 23
8-K
Departure of Directors or Certain Officers
10 Apr 23
EFFECT
Notice of effectiveness
7 Apr 23
ARS
2022 FY
Annual report to shareholders
24 Mar 23
DEFA14A
Additional proxy soliciting materials
24 Mar 23
DEF 14A
Definitive proxy
24 Mar 23
8-K
Other Events
13 Mar 23
S-8
Registration of securities for employees
9 Feb 23
POS AM
Prospectus update (post-effective amendment)
9 Feb 23
10-K
2022 FY
Annual report
9 Feb 23
8-K
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update
9 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
9 Feb 23
8-K
Other Events
9 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
16 Dec 22
8-K
Other Events
12 Dec 22
8-K
Other Events
26 Oct 22
Latest ownership filings
4
Houte Hans van
16 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
4
Houte Hans van
15 Feb 24
4
Christine Ring
15 Feb 24
4
Gwenn Hansen
15 Feb 24
4
ARTHUR T SANDS
15 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
SANDS ARTHUR T
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
WASATCH ADVISORS LP
9 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
4
Houte Hans van
30 Jan 24
4
Gwenn Hansen
30 Jan 24
4
Christine Ring
30 Jan 24
SC 13G
ARK Investment Management LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Houte Hans van
21 Dec 23
4
Houte Hans van
20 Dec 23
144
Notice of proposed sale of securities
19 Dec 23
4
Houte Hans van
1 Nov 23
4
Christine Ring
1 Nov 23
4
Gwenn Hansen
1 Nov 23
4
Houte Hans van
1 Aug 23
4
Christine Ring
1 Aug 23
4
Gwenn Hansen
1 Aug 23
4
Paul M Silva
4 May 23
4
Edward C Saltzman
4 May 23
4
Judith A Reinsdorf
4 May 23
4
David L. Lacey
4 May 23
4
Lori Anne Kunkel
4 May 23
4
JULIA P GREGORY
4 May 23
4
Stefani Wolff
2 May 23
4
Houte Hans van
2 May 23
4
Christine Ring
2 May 23
4
Gwenn Hansen
2 May 23
SC 13G
Deep Track Capital, LP
24 Feb 23